INM (InMed Pharmaceuticals) EV-to-EBIT : -0.14 (As of Apr. 30, 2025)

InMed Pharmaceuticals EV-to-EBIT Chart

InMed Pharmaceuticals Annual Data
	Trend	Jun15	Jun16	Jun17	Jun18	Jun19	Jun20	Jun21	Jun22	Jun23	Jun24
EV-to-EBIT		Get a 7-Day Free Trial					-2.84	-1.86	-0.17	0.65	0.40

InMed Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EV-to-EBIT	Get a 7-Day Free Trial															0.89	0.66	0.40	0.19	-0.12

Competitive Comparison of InMed Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InMed Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's EV-to-EBIT falls into.

InMed Pharmaceuticals EV-to-EBIT Calculation

InMed Pharmaceuticals's EV-to-EBIT for today is calculated as:

InMed Pharmaceuticals's current Enterprise Value is $1.09 Mil.
InMed Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InMed Pharmaceuticals  (NAS:INM) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

InMed Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

InMed Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2024 was $0.96 Mil.
InMed Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InMed Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

InMed Pharmaceuticals Business Description